Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | TP53 | P04637 | 5/20 | 0.66 |
| ▸ | POLB | P06746 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896188 | 0.86 | POLB (0.76) | MAPTTP53POLBALDH1A1LMNA | |
| SCHEMBL16896033 | 0.85 | LMNA (0.70) | MAPTTP53POLBALDH1A1LMNA | |
| SCHEMBL20096187 | 0.84 | ALDH1A1 (0.85) | MAPTTP53POLBALDH1A1LMNA | |
| SCHEMBL16896230 | 0.82 | TP53 (0.73) | MAPTTP53POLBALDH1A1LMNA | |
| SCHEMBL16896210 | 0.81 | TP53 (0.68) | MAPTTP53POLBALDH1A1LMNA | |
| SCHEMBL16903565 | 0.80 | MAPT (0.80) | MAPTTP53LMNATHRB | |
| SCHEMBL16896197 | 0.79 | LMNA (0.68) | MAPTTP53POLBALDH1A1LMNA | |
| SCHEMBL20089845 | 0.79 | LMNA (0.68) | MAPTTP53POLBALDH1A1LMNA | |
| SCHEMBL16896201 | 0.79 | TP53 (0.69) | MAPTTP53POLBALDH1A1LMNA | |
| SCHEMBL16896220 | 0.79 | TP53 (0.68) | MAPTTP53POLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505768-B2 | Compositions and methods for modulating TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505768-B2 | Compositions and methods for modulating TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150197527-A1 | COMPOSITIONS AND METHODS FOR MODULATING TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-07-16 | — | — | US | disclosed |
| US-20150197527-A1 | COMPOSITIONS AND METHODS FOR MODULATING TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197527-A1 | COMPOSITIONS AND METHODS FOR MODULATING TLR4 | TLR4, TLR3, TLR6 | MAPT 3892/4885TP53 1455/4885POLB 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.